TLR7 and neoplasm: To achieve this, a liposomal platform system was designed based on co-formulation of a potent TLR7/8 agonist and tumor antigens incorporated into the surface through flexible reducible linkers that upon intracellular reduction release the antigen within phagocytic cells (Fig. 1A).